Elon Musk's AI chatbot, Grok, is being used by X users for medical image analysis, raising both hopes and concerns. While ...

Discover whether it's possible to have mixed dementia, specifically a combination of Alzheimer's and Lewy body dementia. This ...

A paper titled "Deep Learning and Transfer Learning for Brain Tumor Detection and Classification" published in Biology ...

A new study finds that brain shrinkage in Alzheimer’s disease varies greatly among individuals, with distinct patterns rather than a uniform progression. These findings may pave the way for ...

A quick finger prick and a few drops of blood on a card that can be sent in regular mail. This approach could soon make Alzheimer's testing much more accessible worldwide.

That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...

Researchers have created a highly detailed cellular map of Alzheimer’s disease progression, revealing new insights into the ...

A once-a-day pill that targets the production of the stress hormone cortisol in the brain has the potential to be the “holy ...

The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...

US regulators approved Leqembi in 2023 and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved the ...

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...

Most discontinued anti-tau antibodies (red) targeted tau’s N-terminus. Of the antibodies currently in trials (green), bepranemab and E2814 presented results at CTAD, while JJ-63733657/posdinemab and ...